Recent news on Pegasys

Cure for Hepatitis C Announced  -  25 May 2007
EndoNurse,...viral response (SVR) following treatment with either Pegasys (peginterferon alfa-2a) monotherapy or combination therapy with Pegasys and ribavirin.

PEGASYS® Study Authors Conclude that Patients Successfully Treated ...  -  May 22, 2007
WebWire (press release),...(Studies show that, overall, about half of patients with hepatitis C monoinfection can achieve an SVR with PEGASYS and ribavirin treatment,

Data Suggest that PEGASYS® May be an Option in Hepatitis C ...  -  May 21, 2007
WebWire (press release),Furthermore, 92 percent of these patients were able to go on and complete a full course of treatment with PEGASYS. The data, which were presented at the

Roche to invest 190 mln sfr in new production facility in Kaiseraugst  -  May 22, 2007
Forbes,...it is building this new facility in order to meet increasing demand for cancer drugs Avastin, Herceptin and MabThera as well as hepatitis drug Pegasys.

Human Genome Sciences Announces First Quarter 2007 Financial ...  -  May 9, 2007
Earthtimes.orgAlbuferon requires half as many injections, and results to date suggest that Albuferon may offer efficacy at least comparable to Pegasys, with the potential

'Louie, me and hepatitis C'  -  May 4, 2007
BBC News,So she decided to embark on the Pegasys, or pegylated interferon, treatment - a version of a naturally occurring molecule - and chronicles her progress in

HIV and Hepatitis Therapies Continue to Drive Revenues in ...  -  May 23, 2007
PR Web (press release),Roche has gained market share following the launch of Pegasys, which it has bundled with its own ribavarin (Copegsys), while Schering-Plough markets its PEG

Cure for Hep C?  -  May 21, 2007
Ivanhoe,The study was designed to see if the hepatitis C virus (HCV) re-emerged in 997 patients who were successfully treated with either Pegasys (peginterferon

MIGENIX to Present Celgosivir Phase II Hepatitis C Results at ...  -  May 18, 2007
CNW Telbec (Communiqués de presse),In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys,

Maxygen Reports First Quarter 2007 Financial Results  -  May 8, 2007
PR Newswire (press release),The highest of the three doses has been shown in vitro to have five times the antiviral activity of Pegasys(R). "We were pleased to report positive progress

Councilmen's plates are full with variety of issues  -  May 2, 2007
Sioux City Journal,That was the question from Councilman Dave Ferris on a proposal to buy 2000 Pegasys Security System Identification badges for Sioux Gateway Airport from

Roche updates on flu manufacturing; expands US unit  -  Apr 26, 2007
OutSourcing-Pharma.com,...including cancer drug Xeloda (capecitabine), Pegasys (peginterferon alfa-2a) for hepatitis, Tamiflu and Xenical (orlistat) for obesity.

Jets host arch rival in league game  -  Apr 25, 2007
Enid News & Eagle,Today’s games will be taped by Pegasys for broadcast at a later date. Buck King will do the play by play and Rick Evans will do the commentary.

Roche updates on flu manufacturing; expands US unit  -  26 Apr 2007
In-PharmaTechnologist.com,...including cancer drug Xeloda (capecitabine), Pegasys (peginterferon alfa-2a) for hepatitis, Tamiflu and Xenical (orlistat) for obesity.

Jets host arch rival in league game  -  26 Apr 2007
Enid News & Eagle,Today’s games will be taped by Pegasys for broadcast at a later date. Buck King will do the play by play and Rick Evans will do the commentary.

PEGASYS jumps into the world  -  Apr 24, 2007
Enid News & Eagle,...“We want to ensure PEGASYS remains a valuable service to the community of Enid for a long time. With these investments and careful management of our money,

Vertex Vibrates Hepatitis Drug Sector  -  Apr 23, 2007
TheStreet.comVertex is using Roche's version of long-acting interferon alpha, called Pegasys, in all the clinical trials for Vertex's telaprevir hepatitis C drug.

LGE graduation set  -  Apr 24, 2007
Enid News & Eagle,Groendyke; Stephanie Whetrzak, PEGASYS; David Phipps, StarTek; Robert Figuly, StarTek; Joanne Carrube, Northern Oklahoma Resource Center of Enid;

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
campus med,Patients with genotype 1 hepatitis C (HCV) who clear the virus within a month of starting treatment with PEGASYS (peginterferon alfa-2a (40KD)) plus COPEGUS

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
Juraforum.de,The results of theanalysis showed that of those patients treated with PEGASYS 180 mcgweekly plus COPEGUS 1000-1200 mg daily:

APS: Treatment Optimisation With PEGASYS Plus COPEGUS Offers .....  -  Apr 12, 2007
ANP Pers Support,...clinical practice and are relevant to the patients we see every day. At the moment,. testing viral levels at 4 weeks of treatment is not standard practice.

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Apr 6, 2007
Drug Newswire (press release),Some hepatitis C patients with difficult-to-treat HCV genotype 1 who respond quickly to treatment with a combination of PEGASYS(R) (pegylated interferon

Human Genome Sciences reports results of phase 2b trial of Albuferon  -  Apr 17, 2007
News-Medical.net,Pegasys. The treatment group receiving Albuferon 900-mcg doses every two weeks achieved a 59% rate of sustained virologic response at 12 weeks following

Wockhardt opposes Roche patent on Pegasys  -  Mar 29, 2007
Moneycontrol.com,The country's first product patent, granted in the amended patent regime to Swiss pharmaceutical company Roche on its Hepatitis C drug Pegasys,

Vertex's Billion Dollar Drug?  -  Apr 18, 2007
Motley FoolComparing the Prove-1 study results to pivotal studies that helped lead to the approval of Pegasys and Peg-Intron shows the promise that telaprevir therapy

Human Genome reports positive Albuferon study  -  Apr 14, 2007
MarketWatch...achieved a 59% rate of sustained virologic response at 12 weeks following completion of therapy compared with patients who received the drug Pegasys on a

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Apr 6, 2007
Drug Newswire (press release),The trial, known as PROGRESS (PEGASYS and Ribavirin Optimized in Genotype 1 high viRal load patiEntS to improve SVR), will examine the benefits of using a

Idenix Midstage Study Results Mixed  -  Apr 12, 2007
Forbes,Idenix was conducting two midstage Phase IIb clinical trials for the company's valopicitabine and Pegasys combination. The first trial involved 173 patients

Idenix Midstage Studies Fall Short  -  Apr 12, 2007
Forbes,The midstage Phase IIb clinical trials for the company's valopicitabine and Pegasys combination did not result in enough patients responding to the

InterMune's Pre-clinical Data On ITMN-191 Demonstrate High In ...  -  Apr 11, 2007
Trading Markets,One of the experiments, in which the activity of ITMN-191 was studied alone or in combination with Roche's Pegasys in an in vitro model of HCV clearance,

Human Genome Sciences Reveals Positive Interim Results Of Phase 2b ...  -  Apr 16, 2007
Trading Markets,1 chronic hepatitis C. The interim results of the Phase 2b trial demonstrated that Albuferon provided at least comparable efficacy as against Pegasys.

New deals for ProBioGens cell engineering group  -  Apr 25, 2007
In-PharmaTechnologist.com,It also sells biosimilar versions of interferon alfa-2a and pegylated interferon alfa-2a., sold by Roche as Roferon-A and Pegasys, respectively.

Human Genome Sciences Reveals Positive Interim Results Of Phase 2b ...  -  Apr 14, 2007
Trading Markets,The interim results of the Phase 2b trial demonstrated that Albuferon provided at least comparable efficacy as against Pegasys. The results were presented

Nautilus Biotech Begins Phase I Clinical Trial in the USA for ...  -  Apr 6, 2007
Drug Newswire (press release),...the trial is to evaluate SC Belerofon in healthy adult subjects, for safety, tolerability and pharmacokinetics in comparison with IntronA and Pegasys.

Vertex shares continue to climb  -  Apr 5, 2007
Boston Globe,The Phase II clinical trial tests a 12-week regimen of Telaprevir and Roche’s Pegasys interferon product along with the antiviral drug ribavirin to see how

Vertex Shares Up a Study Data Nears  -  Apr 5, 2007
Houston Chronicle,The Phase II clinical trial tests a 12-week regimen of Telaprevir and Roche's Pegasys interferon product along with the antiviral drug ribavirin to see how

Nautilus Biotech begins phase I comparison study  -  Apr 2, 2007
Pharmaceutical Business Review...doses of subcutaneous (SC) Belerofon, which will be compared to SC administered IntronA, manufactured by Schering-Plough and Pegasys, manufactured by Roche.

Dr. Martin Luther King Jr. Holiday Commission  -  Mar 29, 2007
Enid News & Eagle,Norwood is the representative from Southern Heights Community Organization. Stephanie Wnetrzak, representing PEGASYS, was elected vice president.

Someone should be held accountable for bridge collapse  -  Mar 27, 2007
Enid News & Eagle,I recently watched the city council meeting on PEGASYS and I commend those members who want answers and accountability. I have little respect for those who

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),Roche’s hepatitis C franchise started the year well with sales growth of 15% for Pegasys, coupled with approval and launch of companion antiviral Copegus in

Sun shines on Christmas in Action volunteers’ work Saturday  -  Apr 22, 2007
Enid News & Eagle,AE Howard, Hughes Lumber, Homesellers Real Estate, PEGASYS, The Rocket 104.7 and Northern Okla-homa Development Autho-rity’s Area Agency on Aging.

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),Pegasys(R) is registered trademarks of Hoffmann-La Roche, Inc. TaqMan(R) is a registered trademark of Roche Molecular Systems, Inc. 1 Fried, M. et al.,

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PharmaLive.com (press release),Pegasys(R) is registered trademarks of Hoffmann-La Roche, Inc. TaqMan(R) is a registered trademark of Roche Molecular Systems, Inc.

Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 18, 2007
PipelineReview.com (press release),...two of which Enzon markets, Adagen(R) and Oncaspar(R), and three for which Enzon receives royalties, PEG-INTRON(R), Pegasys(R), and Macugen(R).

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),...two of which Enzon markets, Adagen® and Oncaspar®, and three for which Enzon receives royalties, PEG-INTRON®, Pegasys®, and Macugen®.

Enzon’s PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 17, 2007
Business Wire (press release),...two of which Enzon markets, Adagen ® and Oncaspar ® , and three for which Enzon receives royalties, PEG-INTRON ® , Pegasys ® , and Macugen ® .

Vertex to meet hepatitis C patients' needs?  -  Apr 17, 2007
LabTechnologist.com,...with Roche's pegylated interferon Pegasys (peginterferon alfa-2a; peg-IFN) and ribavirin (RBV) enabled some patients to clear the virus in 12 weeks.

Management of Cherokee Strip Conference Center to be turned over ...  -  Apr 16, 2007
Enid News & Eagle,He indicated the city may try to keep Main Street in another office in the conference center, which also houses PEGASYS and Enid Community Founda-tion.

Sustained Response to Anti-Hepatitis C Virus Drugs Results in Cure ...  -  Apr 16, 2007
DG News...had achieved a SVR after treatment with alpha peginterferon alfa-2a (40 KD) (Pegasys(R)) as monotherapy or in combination with ribavirin (Copegus(R)).

Hepatitis C Patients With Advanced Kidney Disease Benefit From ...  -  Apr 16, 2007
DG News...[Presentation title: Use of Low-Dose Peginterferon Alfa-2a (40KD) (Pegasys) to Treat Hepatitis C-Infected, End-Stage Renal Disease Patients undergoing

Vertex Pharmaceuticals - Interim Results Presented at EASL from ...  -  Apr 16, 2007
Oxfordshire Bioscience Network (press release),In these clinical trials, telaprevir is being dosed as 750 mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys®), both with and

Medical Edge: Benefits of hepatitis C drugs outweigh side effects  -  Apr 14, 2007
Bryan College Station Eagle,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as hepatitis C virus.

Innovative Pulmonary & PEGylation-based Therapeutic Product ...  -  Apr 14, 2007
Medical News Today (press release),Nektar PEGylation Technology is also used in eight additional approved partnered products in the US or Europe today, including Roche's PEGASYS® for

Kudos letter: PEGASYS media day goes well for students  -  Mar 17, 2007
Enid News & Eagle,I would like to give a huge thank you to all of the sponsors for PEGASYS’ Northwest Oklahoma High School Media Day. Thank you to Jim and June Butricks,

New Trial Examines Fixed Dose Induction of PEGASYS® in Patients ...  -  Mar 14, 2007
EndoNurse,This study will evaluate the effect of PEGASYS® (peginterferon alfa-2a) and ribavirin in patients who have a high level of genotype 1 virus in their blood

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
PR Newswire UK (press release),Some hepatitis C patients with difficult-to-treat HCV genotype 1 who respond quickly to treatment with a combination of PEGASYS(R) (pegylated interferon

The NHI Drug Reimbursement Price Listing and Launch of the ...  -  Mar 16, 2007
PharmaLive.com (press release),Chairman and CEO: Franz B. Humer) for use in combination with Pegasys® for treating chronic hepatitis C. In Japan, Copegus® obtained approval for the

Roche starts PROGRESS trial in Poland  -  Mar 21, 2007
Polish Market,The international study will evaluate the effect of Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) in hepatitis C patients who have a high

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
PR-Inside.com (Pressemitteilung),The trial, known as PROGRESS (PEGASYS and Ribavirin Optimized in Genotype 1 high viRal load patiEntS to improve SVR), will examine the benefits of using a

- New International Trial Called PROGRESS Starts in 15 Countries  -  Mar 14, 2007
Juraforum.de,The trial, knownas PROGRESS (PEGASYS and Ribavirin Optimized in Genotype 1 high viRalload patiEntS to improve SVR), will examine the benefits of using

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
Earthtimes.orgThetrial, known as PROGRESS (PEGASYS and Ribavirin Optimized in Genotype 1 highviRal load patiEntS to improve SVR), will examine the benefits of using

Human Genome Sciences Announces Positive Interim Results of Phase ...  -  Feb 27, 2007
PR Newswire (press release),Albuferon 900-mcg dosed every two weeks achieved a higher SVR12 rate and more favorable quality-of-life scores than the Pegasys treatment group 73% of

Human Genome Sciences Announces Positive Interim Results of Phase ...  -  Feb 27, 2007
PR Newswire (press release),..."The results suggest that Albuferon may offer comparable or improved efficacy versus Pegasys, with half the injections and the potential for less impairment

Human Genome Touts Interim Study Results  -  Feb 27, 2007
Forbes,The Phase IIb clinical trial compared a combination of Albuferon and ribavirn with Pegasys in patients with genotype 1 chronic hepatitis C. Additionally,

Roche Launches Hepatitis C Therapy in Japan  -  Mar 16, 2007
Reuters.uk,VX: Quote, Profile , Research) said on Friday it had launched Copegus as a combination therapy with Pegasys for patients with chronic hepatitis C in Japan.

Amateur photographers invited to enter contest  -  Mar 6, 2007
Enid News & Eagle,Submit entries to Enid Rotary Club, P,O. Box 1181, Enid, OK 73702-1181; Wendy Quarles at PEGASYS, 123 W. Maine; or wquarles@pegasys.org.

Medical Edge -- Hepatitis C treatment an ordeal worth enduring  -  Mar 12, 2007
Post-Bulletin,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as HCV. Although ribavirin doesn't

Area students learn about communication careers at annual event  -  Feb 28, 2007
Enid News & Eagle,But for now the Pioneer High School senior settled for working the camera and sound board at PEGASYS Wednesday during the annual Northwest Oklahoma High

Despite obstacles, student journalists try to persevere  -  Feb 28, 2007
Enid News & Eagle,I always get a little depressed every year after I come back from doing my speel at the PEGASYS Northwest Oklahoma High School Media Day.

UPDATE 1-Human Genome loss narrows; drug shows positive results  -  Feb 27, 2007
ReutersVX: Quote, Profile , Research) Pegasys. The company started late-stage trials of Albuferon, being developed with Novartis AG (NOVN.

UPDATE 1-Human Genome loss narrows; drug shows positive results  -  Feb 27, 2007
ReutersAlbuferon, along with ribavirin may offer comparable or improved efficacy versus Roche Holding AG's (ROG.VX: Quote, Profile, Research) Pegasys. Continued

Human Genome says antiviral drug shows positive results  -  Feb 27, 2007
ReutersVX: Quote, Profile, Research) Pegasys. The company said it started late-stage trials of Albuferon, being developed with Novartis AG (NOVN.

Human Genome says antiviral drug shows positive results  -  Feb 27, 2007
ReutersVX: Quote, Profile , Research) Pegasys. The company said it started late-stage trials of Albuferon, being developed with Novartis AG (NOVN.

Pharma Sector: Few Newsmakers Of The Week - Lilly, Novartis ...  -  Mar 5, 2007
Trading Markets,The fourth treatment group was subcutaneously administered Pegasys once a week. All patients received oral ribavirin daily.

Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG ...  -  Mar 14, 2007
PipelineReview.com (press release),Nektar PEGylation technology is used in eight approved products in the US and/or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's

Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG ...  -  Mar 13, 2007
Business Wire (press release),Nektar PEGylation technology is used in eight approved products in the US and/or Europe today, including Roche’s PEGASYS® for hepatitis C and Amgen’s

HIV/Hepatitis Coinfection  -  Mar 13, 2007
Medscape (subscription)...and he just presented and summarized the main results from the 3 randomized clinical trials, APRICOT [AIDS PEGASYS Ribavirin International Coinfection

Human Genome Sciences Initiates Phase 3 Clinical Trial of ...  -  Feb 28, 2007
PharmaLive.com (press release),...on health-related quality of life of Albuferon in combination with ribavirin, versus PEGASYS (peginterferon alfa-2a) in combination with ribavirin.

Human Genome Sciences Announces Financial Results for 2006 and ...  -  Feb 27, 2007
PR Newswire (press release),Pegasys in combination with ribavirin in patients with chronic hepatitis C genotype 1. In a separate press release issued earlier today, HGS announced the

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional